Last reviewed · How we verify
NCT06885424: DESCENT-1
A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products
trial testing No additional intervention administered in this long term follow-up study in Solid Tumor Cancer in 400 participants. Enrolling by invitation.
31 March 2030
Quick facts
| Lead sponsor | A2 Biotherapeutics Inc. |
|---|---|
| Status | ENROLLING BY INVITATION |
| Study type | OBSERVATIONAL |
| Enrollment | 400 |
| Start date | 31 August 2025 |
| Primary completion | 31 March 2030 |
| Estimated completion | 31 March 2040 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- No additional intervention administered in this long term follow-up study
Conditions studied
- Solid Tumor Cancer — all drugs for Solid Tumor Cancer →
- Solid Tumor, Unspecified, Adult — all drugs for Solid Tumor, Unspecified, Adult →
- Colorectal Carcinoma — all drugs for Colorectal Carcinoma →
- Colorectal Carcinoma (CRC) — all drugs for Colorectal Carcinoma (CRC) →
Sponsor
A2 Biotherapeutics Inc. — full company profile →
Who can join
18 and older, any sex, with Solid Tumor Cancer or Solid Tumor, Unspecified, Adult. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This protocol is to ensure consistent long-term follow-up for delayed safety events in participants who received A2 Bio gene therapy (GT) products.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Advancements in Targeted Therapies for Colorectal Cancer: Overcoming Challenges and Exploring Future Directions.
Khelwatty SA, Puvanenthiran S, Seddon AM, Bagwan I, et al · · 2025 · cited 1× · PMID 40940907 · DOI 10.3390/cancers17172810
Verify or expand the search:
- PubMed search for NCT06885424
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Solid Tumor Cancer
Currently open trials in the same condition.
- NCT06802172 — Effect of Meal Timing During Cancer Treatment in Patients in Alaska: A Randomized Clinical Trial · NA · recruiting
- NCT07441174 — IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Soli · Phase 1, PHASE2 · recruiting
- NCT07218874 — Feasibility and Acceptability of the Remote Oncology Symptom Assessment Application · NA · recruiting
- NCT07269899 — A Phase I Study of WTX212A Monotherapy or in Combination With Radiotherapy in Patients With Advanced Solid Tumors · Phase 1 · recruiting
- NCT07146672 — Exploratory Study of Super DC Cell Injection in Preventing Recurrence After Radical Surgery for Tumors · Phase 1, PHASE2 · recruiting
Other A2 Biotherapeutics Inc. trials
Trials by the same sponsor.
- NCT06682793 — A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06885424 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by A2 Biotherapeutics Inc.
- Last refreshed: 15 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06885424.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing